呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

Clin Interv Aging：瑞芬太尼用于预防老年患者麻醉剂出现咳嗽的效应部位浓度存在性别差异

2018-07-29 MedSci MedSci原创

关注

考虑到其危险的并发症，应该预防麻醉剂出现的咳嗽。瑞芬太尼的靶控输注（TCI）可以有效地减少出现咳嗽，并且在年轻患者中评估了瑞芬太尼的效应部位浓度（Ce）的性别相关差异。在这项研究中，我们确定了瑞芬太尼用于预防男性和女性老年患者拔管后出现咳嗽的Ce，并评估了与性别相关的差异。研究招募了23名的男性和22名女性老年患者，年龄在60至75岁之间。使用七氟醚和瑞芬太尼TCI维持麻醉。根据Dixon的上下方

考虑到其危险的并发症，应该预防麻醉剂出现的咳嗽。瑞芬太尼的靶控输注（TCI）可以有效地减少出现咳嗽，并且在年轻患者中评估了瑞芬太尼的效应部位浓度（Ce）的性别相关差异。在这项研究中，我们确定了瑞芬太尼用于预防男性和女性老年患者拔管后出现咳嗽的Ce，并评估了与性别相关的差异。

研究招募了23名的男性和22名女性老年患者，年龄在60至75岁之间。使用七氟醚和瑞芬太尼TCI维持麻醉。根据Dixon的上下方法，使用等张回归方法和自举方法确定每种性别的瑞芬太尼用于预防出现咳嗽的Ce。

结果显示，用于预防出现咳嗽的瑞芬太尼的Ce在50％（EC50）和95％（EC95）在女性患者中显著低于男性患者。等渗回归显示瑞芬太尼的EC50（83％置信区间[CI]）在女性中为1.67（1.55-1.83）ng/mL，在男性中为2.60（2.29-2.91）ng/mL。瑞芬太尼的EC95（95％CI）在女性中为2.30（2.02-2.62）ng/mL，在男性中为3.41（3.27-3.58）ng/mL。Dixon的上下方法表明，女性的平均EC50低于男性（1.56±0.26 ng/mL vs 2.56±0.37 ng/mL，P <0.001）。

综上所述，该研究结果表明，瑞芬太尼预防出现咳嗽的要求在女性中低于男性老年患者，表明瑞芬太尼Ce的性别相关差异。使用瑞芬太尼TCI预防老年患者出现咳嗽时应考虑性别因素。

原始出处：

Lee SY, Jeong YY, et al., Sex-related differences in effect-site concentration of remifentanil for preventing anesthetic emergence cough in elderly patients. Clin Interv Aging. 2018 Jan 5;13:81-89. doi: 10.2147/CIA.S151476. eCollection 2018.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1384819, encodeId=bde6138481915, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405261, encodeId=035114052612e, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544538, encodeId=4569154453842, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335192, encodeId=0d1833519231, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 30 22:52:03 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334954, encodeId=556c3349541f, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jul 29 18:40:36 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-31 xue8602

    #芬太尼#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1384819, encodeId=bde6138481915, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405261, encodeId=035114052612e, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544538, encodeId=4569154453842, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335192, encodeId=0d1833519231, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 30 22:52:03 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334954, encodeId=556c3349541f, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jul 29 18:40:36 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-31 qidongfanjian

    #瑞芬太尼#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1384819, encodeId=bde6138481915, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405261, encodeId=035114052612e, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544538, encodeId=4569154453842, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335192, encodeId=0d1833519231, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 30 22:52:03 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334954, encodeId=556c3349541f, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jul 29 18:40:36 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-31 12498974m55暂无昵称

    #浓度#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1384819, encodeId=bde6138481915, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405261, encodeId=035114052612e, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544538, encodeId=4569154453842, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335192, encodeId=0d1833519231, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 30 22:52:03 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334954, encodeId=556c3349541f, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jul 29 18:40:36 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-30 1ddf0692m34(暂无匿称)

    学习了，长知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1384819, encodeId=bde6138481915, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405261, encodeId=035114052612e, content=<a href='/topic/show?id=568068e40fa' target=_blank style='color:#2F92EE;'>#瑞芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68740, encryptionId=568068e40fa, topicName=瑞芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2a92531888, createdName=qidongfanjian, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544538, encodeId=4569154453842, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Jul 31 07:08:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335192, encodeId=0d1833519231, content=学习了，长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Jul 30 22:52:03 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334954, encodeId=556c3349541f, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sun Jul 29 18:40:36 CST 2018, time=2018-07-29, status=1, ipAttribution=)]
    2018-07-29 1ddf0692m34(暂无匿称)

    学习了，谢谢分享

    0